Running a plaintiff PI firm on lien-based cases is a different business than running one on hourly or insurance-defense work. The math is opaque to outsiders, the cash flow is volatile, and the working-capital requirements scale with caseload in ways that surprise lawyers who started small and grew without thinking carefully about the underlying finance model. This piece is the publisher's view on what that model actually looks like in 2026.
The first thing to understand: this is a finance business with a law firm attached
A plaintiff PI firm running on lien-based cases is, financially, a specialty receivables business. The firm advances costs against a portfolio of contingent claims, with the claims maturing at unpredictable intervals over twelve to thirty-six months. The cost-of-prosecution sits on the firm's books as a working-capital outlay until each individual case settles or judgment is collected. The collections at the end are paid out to medical providers, lienholders, the client, and the firm in priority order — with the firm typically last in line by the time the math actually closes.
A firm running fifty open files has fifty parallel receivable positions, each with its own maturity, its own expected return, and its own risk profile. The right way to think about the practice is as a portfolio. Anything less than that view will eventually break the firm's cash position at the wrong moment.
The cost-of-prosecution stack
The firm fronts costs on every case. Filing fees, deposition costs, expert retainers, medical record requests, court reporters, mediation fees, trial-prep production, demonstrative exhibits. On a moderate case headed to trial, the cost-of-prosecution can hit $50,000 to $150,000. On a catastrophic-injury or trucking case, it can clear $500,000. The firm carries every dollar of that on its working-capital line until the case closes.
What plaintiff lawyers underestimate at the smaller-firm size is how nonlinear the cost-of-prosecution scales. The first ten cases cost the firm fifty thousand dollars in advanced expenses. The next ten cost two hundred fifty thousand because the case mix shifted toward heavier matters. The next ten cost six hundred thousand because two of them went to trial preparation simultaneously and overlapped on expert workups. The working-capital demand is not a linear function of caseload; it is a function of caseload weighted by case profile, and it can jump in step changes that catch unprepared firms in a cash-position squeeze.
Provider lien financing as a quasi-balance-sheet item
The doctor-on-lien arrangement is, in finance terms, a form of supplier credit. The provider extends treatment on a deferred-payment basis with payment contingent on case outcome. The provider becomes a balance-sheet stakeholder in the case alongside the firm and the client. The firm has not paid for the treatment, but the firm is implicitly responsible for managing the relationship with the provider, the documentation that supports the bill at settlement, and the eventual lien negotiation.
This is where vetting matters financially, not just legally. A firm with a referral matrix populated by reasonable, well-documented, settlement-savvy providers is a firm with a more manageable lien-negotiation workload at closing. A firm with a referral matrix populated by aggressive billers and reluctant negotiators is a firm where every closing is a fight, and every fight consumes the senior lawyer time that should be billable to the next case. For the operational view on vetting, see the doctor-on-lien checklist.
Working-capital sources
Plaintiff PI firms finance the gap between expense outlay and settlement collection through a small set of sources. Each has its own cost and its own structural characteristics.
Bank lines of credit secured by the firm's expected receivables. Available to established firms with a track record. Cost is typically prime plus a small margin. Covenant requirements can be tight, and the bank's case-by-case valuation of receivables is usually conservative.
Specialty litigation-finance lenders. Higher cost, but more flexibility on advance rates and covenants. The cost varies widely; firms negotiating these arrangements should compare effective annualized cost against a bank line wherever both are available.
Partner capital. The cheapest and least flexible source. Many firms run partner capital as the de facto first source and only reach for external credit when growth outpaces internal funding.
Expert and cost advance services. Specialty vendors that finance specific expert work on individual cases, with repayment from the case proceeds. The cost is high, but the funding is matched to the case rather than weighing on the firm-level balance sheet.
A growing firm typically uses two or three of these in combination. The mix shifts as the case portfolio shifts; trucking-heavy and catastrophic-heavy portfolios need different financing profiles than soft-tissue-heavy ones.
The closing-side math
When a case closes, the recovery flows through a priority sequence: medical liens (subject to negotiation, see the lien-mechanics primer), statutory liens like Medi-Cal and ERISA, costs advanced by the firm, the attorney's fee, and finally the client share. Each step has its own discount-and-negotiation profile. The firm's net realization on a settled case is usually substantially below what a naive read of the case file would suggest.
A firm that does not run the closing-side math at intake is a firm that will eventually take cases that look profitable on paper and lose money on after working capital costs and lien recoveries. The discipline is to run a back-of-envelope close estimate at the intake stage, again at the demand-letter stage, and again at the mediation stage. The estimates rarely match. The point is to update the firm's view of the portfolio in close to real time.
The 2026 working-capital environment
Two observations on the current finance environment matter to PI firm partners considering growth. First, bank credit availability for plaintiff firms with documented track records has remained relatively stable through the year, with terms broadly in line with where they were in 2024. Second, the specialty litigation-finance market has continued to mature, with more lenders in the space and somewhat narrower spreads than five years ago. The financing options for a well-run plaintiff firm are better now than they have been in a long time.
The flip side is that case maturities have lengthened. Carriers are slower to settlement than they were in 2022, mediation is harder on mid-range cases (see the verdict pattern piece), and trial dates are routinely set further out. The working-capital cycle has stretched by an average of three to four months across the industry. That extension translates directly into higher financing costs per case.
The portfolio metrics worth tracking
Three numbers I track monthly on every firm I have run or advised:
Cost-advanced-to-recovery ratio — over a rolling twelve-month window. A firm where every dollar of advanced cost is producing $5 of gross recovery is healthier than one where the ratio is $3. The deterioration of this ratio is the first leading indicator of case-selection drift.
Average case-to-close cycle time — days from intake to first settlement check. The single most useful working-capital indicator. When this number drifts upward by twenty percent, the firm's working-capital requirement has just expanded proportionally even if caseload is flat.
Lien-write-down realization — the percentage of medical-specials face value that the firm actually writes the recovery check for, in aggregate. A practice that consistently lands at fifty percent of face is in better shape than one that lands at sixty-five percent. The difference compounds across the portfolio.
For the operational tracking layer that produces these numbers, see building a lien portfolio. The metrics are useless without the underlying tracking discipline.
The risk that ends firms
The risk that has put more plaintiff PI firms into receivership than any other is a concentrated trial loss on a case that exhausted the firm's available working capital. The case was real, the work was good, the trial result was bad, and the firm could not absorb the loss without selling off receivables on the rest of the portfolio at a steep discount. Once that sale happens, the firm's break-even point on the remaining caseload becomes very difficult to clear.
The discipline that protects against this risk is portfolio diversification. No single case should represent more than a modest fraction of the firm's working-capital exposure. The firms that have run for decades and weathered multiple cycles are the firms that ran a portfolio, not a hero file. The whole game in plaintiff PI practice, after the cases themselves, is to keep the portfolio diversified enough that no single bad outcome ends the operation.